In Q4 2025, Relay generated 7000000 in license revenue and narrowed its net loss to 54889000 as research and administrative expenses declined year-over-year, ending the quarter with over 554000000 in cash and investments.

Relay Therapeutics reported a net loss of $77.1 million for Q1 2025, with total revenue of $7.7 million. The company extended its cash runway into 2029 through strategic cost reductions and expects to fully fund key initiatives, including the ReDiscover-2 trial and vascular malformations clinical proof-of-concept data.

Relay Therapeutics reported no revenue for Q4 2024. Cash, cash equivalents, and investments totaled $781.3 million. Net loss was $76.0 million, or $0.45 per share. The company anticipates initiating the Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant in mid-2025.

Relay Therapeutics reported no revenue for Q3 2024, compared to $25.2 million in Q3 2023. Research and development expenses were $76.6 million, down from $81.5 million year-over-year. The company's net loss was $88.1 million, or $0.63 per share, compared to a net loss of $65.7 million, or $0.54 per share, in the prior year. They ended the quarter with approximately $840 million in cash, cash equivalents and investments, expected to fund operations into the second half of 2027.

Relay Therapeutics reported second quarter 2024 financial results, highlighting progress in clinical programs and expansion of the RLY-2608 development program. The company announced new pre-clinical programs and anticipates multiple data readouts later in the year. Cash reserves are expected to fund operations into the second half of 2026.

Relay Therapeutics reported a revenue of $10.0 million for the first quarter of 2024, primarily due to a milestone payment from Genentech. The company's cash, cash equivalents, and investments totaled approximately $750 million, expected to fund operations into the second half of 2026. Net loss for the quarter was $81.4 million, or $0.62 per share.

Relay Therapeutics reported its Q4 and full year 2023 financial results, highlighting progress across its portfolio, including advancing multiple clinical programs and investing in its Dynamo platform. The company's cash, cash equivalents, and investments totaled approximately $750 million at the end of Q4 2023, expected to fund operations into the second half of 2026.